NCT07441993 Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 30 participants in total. It began in 2026-01-05 with a primary completion date of 2027-12.

Brief Summary

This is a single-arm, multicenter, prospective, phase II study. The primary objective is to assess the efficacy and safety of orelabrutinib in treatment-naïve patients with marginal zone lymphoma.

Eligibility Criteria

Inclusion Criteria: 1. Age ≥18 years, regardless of gender; 2. Patients with histopathologically confirmed stage I/II marginal zone lymphoma; 3. ECOG performance status score of 0-2; 4. Major organ functions meeting the following criteria: 1. Blood tests: Absolute neutrophil count (ANC) ≥1.5×10\^9/L, platelets ≥75×10\^9/L, hemoglobin ≥75g/L; if accompanied by bone marrow involvement, ANC ≥1.0×10\^9/L, platelets ≥50×10\^9/L, hemoglobin ≥50g/L; 2. Blood biochemistry: Total bilirubin ≤1.5×ULN, AST or ALT ≤2×ULN; serum creatinine ≤1.5×ULN; 5. Coagulation function: International normalized ratio (INR) ≤1.5×ULN; 6. Expected survival time ≥12 months; 7. Voluntary written informed consent signed before trial screening. Exclusion Criteria: 1. Lymphoma involving the central nervous system or transformation to high-grade; 2. Uncontrolled or significant cardiovascular diseases, including: 1. New York Heart Association (NYHA) Class II or higher congestive heart failure, unstable angina, myocardial infarction within 6 months prior to the first dose of the study drug, or arrhythmia requiring treatment at screening, with left ventricular ejection fraction (LVEF) \<50%; 2. Primary cardiomyopathy (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, or unclassified cardiomyopathy); 3. History of clinically significant QTc interval prolongation, or QTc interval \>470 ms for females or \>450 ms for males at screening; 4. Subjects with symptomatic coronary artery disease requiring medication; 5. Poorly controlled hypertension (failure to achieve target blood pressure after at least one month of lifestyle modification and treatment with three or more antihypertensive drugs, including diuretics, at maximally tolerated doses, or requiring four or more antihypertensive drugs for effective control). 3. Active bleeding within 2 months prior to screening, or current use of anticoagulants, or investigator-determined clear bleeding tendency; 4. History of deep vein thrombosis or pulmonary embolism within the past six months; 5. Urine protein ≥2+ and 24-hour urine protein quantification ≥2 g/24 hours; 6. Clinically significant gastrointestinal abnormalities that may affect drug intake, transport, or absorption (e.g., inability to swallow, chronic diarrhea, intestinal obstruction), or subjects with total gastrectomy; 7. Current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, or other conditions affecting lung function; 8. Pregnant or breastfeeding women, or subjects of childbearing potential unwilling to use contraception; 9. Continuous use of drugs with moderate to strong cytochrome P450 CYP3A inhibition or strong induction effects; 10. Other conditions deemed by the investigator as unsuitable for participation in this trial.

Contact & Investigator

Frequently Asked Questions

Related Trials